TY  - JOUR
AU  - Radojević, Branislava
AU  - Dragašević-Mišković, Nataša T.
AU  - Milovanović, Andona
AU  - Svetel, Marina
AU  - Petrović, Igor
AU  - Pešić, Maja
AU  - Tomić, Aleksandra
AU  - Stanisavljević, Dejana
AU  - Savić, Miroslav
AU  - Kostić, Vladimir S.
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4329
AB  - Objectives: Adherence to medication is an important factor that can influence Parkinson's disease (PD) control. We aimed to explore patients' adherence to antiparkinsonian medication and determine factors that might affect adherence to medications among PD patients. Methods: A cross-sectional, exploratory survey of PD patients treated with at least one antiparkinsonian drug and with a total score of MoCA (Montreal Cognitive Assessment) ≥26 was conducted. The final sample included 112 PD patients. A patient's adherence was assessed through ARMS (Adherence to Refills and Medications Scale). ARMS scores higher than 12 were assumed lower adherence. In addition, each patient underwent neurological examination, assessment of depression, anxiety, and evaluation of the presence of PD nonmotor symptoms. Results: The mean ARDS value in our cohort was 14.9 ± 2.5. Most PD patients (74.1%) reported lower adherence to their medication. Participants in the lower adherence group were younger at PD onset, had significantly higher UPDRS (Unified PD Rating Scale) scores, as well as UPDRS III and UPDRS IV subscores, HARS (Hamilton Anxiety Rating Scale), and NMSQuest (Non-Motor Symptoms Questionnaire for PD) scores compared to the fully adherent group (p=0.013, p=0.017, p=0.041, p=0.043, and p=0.023, respectively). Among nonmotor PD symptoms, the presence of cardiovascular, apathy/attention-deficit/memory disorders, hallucinations/delusions, and problems regarding changes in weight, diplopia, or sweating were associated with lower adherence. Multivariate regression analysis revealed depression as the strongest independent predictor of lower adherence. Conclusion: Depressed PD patients compared to PD patients without clinical depression had a three times higher risk for lower adherence to pharmacotherapy. Recognition and adequate treatment of depression might result in improved adherence.
PB  - Hindawi
T2  - International journal of clinical practice
T1  - Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale
VL  - 2022
DO  - 10.1155/2022/6741280
ER  - 

@article{
author = "Radojević, Branislava and Dragašević-Mišković, Nataša T. and Milovanović, Andona and Svetel, Marina and Petrović, Igor and Pešić, Maja and Tomić, Aleksandra and Stanisavljević, Dejana and Savić, Miroslav and Kostić, Vladimir S.",
year = "2022",
abstract = "Objectives: Adherence to medication is an important factor that can influence Parkinson's disease (PD) control. We aimed to explore patients' adherence to antiparkinsonian medication and determine factors that might affect adherence to medications among PD patients. Methods: A cross-sectional, exploratory survey of PD patients treated with at least one antiparkinsonian drug and with a total score of MoCA (Montreal Cognitive Assessment) ≥26 was conducted. The final sample included 112 PD patients. A patient's adherence was assessed through ARMS (Adherence to Refills and Medications Scale). ARMS scores higher than 12 were assumed lower adherence. In addition, each patient underwent neurological examination, assessment of depression, anxiety, and evaluation of the presence of PD nonmotor symptoms. Results: The mean ARDS value in our cohort was 14.9 ± 2.5. Most PD patients (74.1%) reported lower adherence to their medication. Participants in the lower adherence group were younger at PD onset, had significantly higher UPDRS (Unified PD Rating Scale) scores, as well as UPDRS III and UPDRS IV subscores, HARS (Hamilton Anxiety Rating Scale), and NMSQuest (Non-Motor Symptoms Questionnaire for PD) scores compared to the fully adherent group (p=0.013, p=0.017, p=0.041, p=0.043, and p=0.023, respectively). Among nonmotor PD symptoms, the presence of cardiovascular, apathy/attention-deficit/memory disorders, hallucinations/delusions, and problems regarding changes in weight, diplopia, or sweating were associated with lower adherence. Multivariate regression analysis revealed depression as the strongest independent predictor of lower adherence. Conclusion: Depressed PD patients compared to PD patients without clinical depression had a three times higher risk for lower adherence to pharmacotherapy. Recognition and adequate treatment of depression might result in improved adherence.",
publisher = "Hindawi",
journal = "International journal of clinical practice",
title = "Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale",
volume = "2022",
doi = "10.1155/2022/6741280"
}

Radojević, B., Dragašević-Mišković, N. T., Milovanović, A., Svetel, M., Petrović, I., Pešić, M., Tomić, A., Stanisavljević, D., Savić, M.,& Kostić, V. S.. (2022). Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale. in International journal of clinical practice
Hindawi., 2022.
https://doi.org/10.1155/2022/6741280

Radojević B, Dragašević-Mišković NT, Milovanović A, Svetel M, Petrović I, Pešić M, Tomić A, Stanisavljević D, Savić M, Kostić VS. Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale. in International journal of clinical practice. 2022;2022.
doi:10.1155/2022/6741280 .

Radojević, Branislava, Dragašević-Mišković, Nataša T., Milovanović, Andona, Svetel, Marina, Petrović, Igor, Pešić, Maja, Tomić, Aleksandra, Stanisavljević, Dejana, Savić, Miroslav, Kostić, Vladimir S., "Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale" in International journal of clinical practice, 2022 (2022),
https://doi.org/10.1155/2022/6741280 . .

TY  - JOUR
AU  - Radojević, Branislava
AU  - Dragašević-Mišković, Nataša
AU  - Marjanović, Ana
AU  - Branković, Marija
AU  - Milovanović, Andona
AU  - Petrović, Igor
AU  - Svetel, Marina
AU  - Jančić, Ivan
AU  - Stanisavljević, Dejana
AU  - Milićević, Ognjen
AU  - Savić, Miroslav
AU  - Kostić, Vladimir
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4082
AB  - Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.
PB  - Elsevier Ltd
T2  - Parkinsonism and Related Disorders
T1  - The correlation between genetic factors and freezing of gait in patients with Parkinson's disease
VL  - 98
SP  - 7
EP  - 12
DO  - 10.1016/j.parkreldis.2022.03.018
ER  - 

@article{
author = "Radojević, Branislava and Dragašević-Mišković, Nataša and Marjanović, Ana and Branković, Marija and Milovanović, Andona and Petrović, Igor and Svetel, Marina and Jančić, Ivan and Stanisavljević, Dejana and Milićević, Ognjen and Savić, Miroslav and Kostić, Vladimir",
year = "2022",
abstract = "Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.",
publisher = "Elsevier Ltd",
journal = "Parkinsonism and Related Disorders",
title = "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease",
volume = "98",
pages = "7-12",
doi = "10.1016/j.parkreldis.2022.03.018"
}

Radojević, B., Dragašević-Mišković, N., Marjanović, A., Branković, M., Milovanović, A., Petrović, I., Svetel, M., Jančić, I., Stanisavljević, D., Milićević, O., Savić, M.,& Kostić, V.. (2022). The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders
Elsevier Ltd., 98, 7-12.
https://doi.org/10.1016/j.parkreldis.2022.03.018

Radojević B, Dragašević-Mišković N, Marjanović A, Branković M, Milovanović A, Petrović I, Svetel M, Jančić I, Stanisavljević D, Milićević O, Savić M, Kostić V. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders. 2022;98:7-12.
doi:10.1016/j.parkreldis.2022.03.018 .

Radojević, Branislava, Dragašević-Mišković, Nataša, Marjanović, Ana, Branković, Marija, Milovanović, Andona, Petrović, Igor, Svetel, Marina, Jančić, Ivan, Stanisavljević, Dejana, Milićević, Ognjen, Savić, Miroslav, Kostić, Vladimir, "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease" in Parkinsonism and Related Disorders, 98 (2022):7-12,
https://doi.org/10.1016/j.parkreldis.2022.03.018 . .